Last reviewed · How we verify
levo-bupivacaine
Levo-bupivacaine, marketed by Sun Yat-sen University, is an established anesthetic agent with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and recognized efficacy. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | levo-bupivacaine |
|---|---|
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition (PHASE4)
- Thoracic Epidural Analgesia With Bilateral Erector Spinae Plane Block in Radical Cystectomy Surgery (NA)
- AI Prediction of Post-Induction Hypotension in Cesarean Sections With Spinal Anesthesia
- Role of Left Stellate Ganglion Block in Offering Myocardial Protection in On-pump Mitral Valve Replacement? A Histopathological and Clinical Assessment (NA)
- Post-operative Cesarean Trial of Pain Control (NA)
- IPP Placement & Intracavernosal Block (PHASE4)
- Functional Endoscopic Sinus Surgery Study (PHASE1, PHASE2)
- Erector Spınae Plane Block and Transmuscular Quadratus Lumborum Block In Kıdney Transplantatıon (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- levo-bupivacaine CI brief — competitive landscape report
- levo-bupivacaine updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI